2023-09-29 04:41:48 ET
- ModeX Therapeutics, an OPKO Health ( NASDAQ: OPK ) company, has been awarded a contract from the Biomedical Advanced Research and Development Authority, to advance a platform and specific candidates designed to address a range of public health threats in viral infectious diseases.
- The awarded funding will enable research, development and clinical evaluation of potent multispecific antibodies, based on ModeX proprietary MSTAR technology.
- This initiative builds on a collaboration between ModeX and the Vaccine Research Center of the National Institutes of Health for the discovery and characterization of novel therapeutic antibodies against SARS-CoV-2.
- OPK +10.67% premarket to $1.66.
- Source: Press Release
For further details see:
ModeX Therapeutics secures BARDA contract to develop novel multispecific antibodies